Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Prostate Cancer and Prostatic Diseases
|
July 4, 2012
Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist?
N D Shore
The Journal of Urology
|
November 1, 1985
Free autogenous muscle transplantation in rabbits: a technique for correction of urinary incontinence
N D Shore, F H Schachat, L R King
Seminars in Urology
|
August 1, 1987
Indwelling ureteral stents
N D Shore, K J Bregg, R E Sosa
Prostate Cancer and Prostatic Diseases
|
July 4, 2012
New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists
N D Shore, P-A Abrahamsson, J Anderson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 14, 2017
Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302
D Cella, S Traina, T Li, et al.
Cancer Chemotherapy and Pharmacology
|
July 4, 2012
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
A W Tolcher, K N Chi, N D Shore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2011
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial
A J Zurita, D J George, N D Shore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2025
Final overall survival and safety analyses of the phase III PSMAfore trial of [<sup>177</sup>Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
K Fizazi, K N Chi, N D Shore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 22, 2017
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide
D E Rathkopf, M R Smith, C J Ryan, et al.
The Prostate
|
May 6, 2025
Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala Variant
A Mandl, M L Zahurak, N A Metri, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Prostate Cancer and Prostatic Diseases
|
July 4, 2012
Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist?
N D Shore
The Journal of Urology
|
November 1, 1985
Free autogenous muscle transplantation in rabbits: a technique for correction of urinary incontinence
N D Shore, F H Schachat, L R King
Seminars in Urology
|
August 1, 1987
Indwelling ureteral stents
N D Shore, K J Bregg, R E Sosa
Prostate Cancer and Prostatic Diseases
|
July 4, 2012
New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists
N D Shore, P-A Abrahamsson, J Anderson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 14, 2017
Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302
D Cella, S Traina, T Li, et al.
Cancer Chemotherapy and Pharmacology
|
July 4, 2012
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
A W Tolcher, K N Chi, N D Shore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2011
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial
A J Zurita, D J George, N D Shore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2025
Final overall survival and safety analyses of the phase III PSMAfore trial of [<sup>177</sup>Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
K Fizazi, K N Chi, N D Shore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 22, 2017
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide
D E Rathkopf, M R Smith, C J Ryan, et al.
The Prostate
|
May 6, 2025
Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala Variant
A Mandl, M L Zahurak, N A Metri, et al.
Page
of 2